rs137893207
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_001105206.3(LAMA4):c.1673C>T(p.Ala558Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00029 in 1,605,556 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. A558A) has been classified as Likely benign.
Frequency
Consequence
NM_001105206.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
LAMA4 | NM_001105206.3 | c.1673C>T | p.Ala558Val | missense_variant | 14/39 | ENST00000230538.12 | NP_001098676.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
LAMA4 | ENST00000230538.12 | c.1673C>T | p.Ala558Val | missense_variant | 14/39 | 1 | NM_001105206.3 | ENSP00000230538 | A1 | |
ENST00000585373.5 | n.414+912G>A | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.000145 AC: 22AN: 151968Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000759 AC: 19AN: 250312Hom.: 0 AF XY: 0.0000887 AC XY: 12AN XY: 135304
GnomAD4 exome AF: 0.000305 AC: 443AN: 1453470Hom.: 0 Cov.: 28 AF XY: 0.000278 AC XY: 201AN XY: 723638
GnomAD4 genome AF: 0.000145 AC: 22AN: 152086Hom.: 0 Cov.: 32 AF XY: 0.000121 AC XY: 9AN XY: 74348
ClinVar
Submissions by phenotype
not provided Uncertain:3Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jan 13, 2015 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 29, 2024 | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis indicates that this missense variant does not alter protein structure/function - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2023 | LAMA4: BP4, BS2 - |
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jul 07, 2017 | The p.Ala551Val variant (rs137893207) has not been reported in the medical literature; however, it is listed in the ClinVar database as a variant of uncertain significance (Variation ID: 194372). It is listed in the Genome Aggregation Database (gnomAD) browser with an overall frequency of 0.029% (identified in 7 out of 23,984 chromosomes). The alanine at codon 551 is weakly conserved considering 12 species (Alamut software v2.9), and computational analyses suggest this variant does not have a significant effect on LAMA4 protein structure/function (SIFT: tolerated, PolyPhen2: benign, and Mutation Taster: polymorphism). However, based on the available information, the clinical significance of the p.Ala551Val variant cannot be determined with certainty. - |
not specified Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 12, 2015 | Variant classified as Uncertain Significance - Favor Benign. The p.Ala551Val var iant in LAMA4 has not been previously reported in individuals with cardiomyopath y, but has been identified in 6/62116 European chromosomes by the Exome Aggregat ion Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs137893207). Alanin e (Ala) at position 551 is not conserved in evolutionarily distant species with 7 reptiles and birds having a valine (Val) at that position, raising the possibi lity that this change may be tolerated. Other computational prediction tools sug gest that the p.Ala551Val variant may not impact the protein, though this inform ation is not predictive enough to rule out pathogenicity. In summary, while the clinical significance of the p.Ala551Val variant is uncertain, these data sugges t that it is more likely to be benign. - |
Uncertain significance, no assertion criteria provided | clinical testing | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Apr 15, 2014 | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. LAMA4 p.Ala551Val Given the weak gene-phenotype evidence, the lack of case data and presence in unselected individuals (albeit rare), we consider this variant a variant of uncertain significance. LAMA4 variants have been reported in association with DCM, however only minimal evidence is available. Knoll et al (2007) identified LAMA4 as a candidate gene after a zebrafish screen then sequenced in patients with severe DCM and found a missense variant and a nonsense variant. We have not evaluated the strength of this evidence. This variant is novel. The variant was reported online in 8 of 57,245 individuals in the Exome Aggregation Consortium dataset (http://exac.broadinstitute.org/), which currently includes variant calls on ~64,000 individuals of European, African, Latino and Asian descent (as of July 22nd, 2015). Specifically, the variant was observed in 6 of 31,058 European individuals, 1 of 5057 African individuals, and 1 of 5477 Latino individuals. The phenotype of those individuals is not publicly available. The dataset is comprised of multiple cohorts, some of which were recruited from the general population, others were enriched for common cardiovascular disease. Note that other variants with strong evidence for pathogenicity have been seen at similar frequencies in datasets like this so this does not necessarily rule out pathogenicity (Pan et al 2012). - |
Dilated cardiomyopathy 1JJ Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 01, 2023 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 194372). This variant has not been reported in the literature in individuals affected with LAMA4-related conditions. This variant is present in population databases (rs137893207, gnomAD 0.03%). This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 551 of the LAMA4 protein (p.Ala551Val). - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 19, 2021 | - - |
Cardiomyopathy Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Nov 23, 2016 | - - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 14, 2023 | The p.A551V variant (also known as c.1652C>T), located in coding exon 13 of the LAMA4 gene, results from a C to T substitution at nucleotide position 1652. The alanine at codon 551 is replaced by valine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at